Pathophysiology and treatment of pain in joint disease

Adv Drug Deliv Rev. 2006 May 20;58(2):323-42. doi: 10.1016/j.addr.2006.01.011. Epub 2006 Feb 28.

Abstract

Deep somatic pain originating in joints and tendons is a major therapeutic challenge. Spontaneous pain and mechanical hypersensitivity can develop as a consequence of sensitization of primary afferents directly involved in the inflammatory process, but also following sensitization of neuronal processing in the spinal cord (central sensitization) or higher centres. Inflammatory pain is linked to sensitization of sensory proteins at the nociceptive endings whereas pain originating from nerve damage (neuropathic pain) has been linked to changes in axonal ion channels producing ectopic discharge in nociceptors as a source of pain. New targets for analgesic therapy include sensory proteins at the nociceptive nerve endings such as the activating TRPV and ASIC channels, but also inhibitory opioid and cannabinoid receptors. Therapeutic targets are also found among the axonal channels that set membrane potential and modulate discharge frequency such as voltage sensitive sodium channels and various potassium channels.

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis / complications
  • Arthritis / drug therapy
  • Central Nervous System / physiopathology
  • Humans
  • Joint Diseases / complications*
  • Joint Diseases / physiopathology
  • Joint Diseases / therapy*
  • Pain / etiology*
  • Pain / physiopathology
  • Pain Management*
  • Peripheral Nervous System / physiopathology